You are here

  • Home
  • Archive
  • Volume 12, Issue 8
  • Nivolumab maintenance improves overall survival of patients with advanced melanoma who experience severe immune-related adverse events on nivolumab plus ipilimumab

Article metrics

Article menu
Clinical/translational cancer immunotherapy
Original research
Nivolumab maintenance improves overall survival of patients with advanced melanoma who experience severe immune-related adverse events on nivolumab plus ipilimumab

 

Online download statistics by month:

Online download statistics by month: August 2024 to January 2026

AbstractFullPdf
Aug 202427627726
Sep 2024604603259
Oct 202417017095
Nov 202429129381
Dec 202433133652
Jan 202523423477
Feb 202516016159
Mar 202517717763
Apr 202522522581
May 202516316372
Jun 202513113256
Jul 2025111
Jan 2026110
Total27642773922